Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

IGF-axis proteins may have a role in development of type 2 diabetes

Researchers at Albert Einstein College of Medicine of Yeshiva University in collaboration with Nurses' Health Study investigators have shown that levels of certain related proteins found in blood are associated with a greatly reduced risk for developing type 2 diabetes up to a decade or more later. The findings, published today in the online edition of Diabetes, could open a new front in the war against diabetes.

4 May 2012

High fructose intake may increase risk of NFALD in obese people

Obese people who consume increased amounts of fructose, a type of sugar that is found in particular in soft drinks and fruit juices, are at risk for nonalcoholic fatty liver disease (NFALD) and more its more severe forms, fatty inflammation and scarring.

3 May 2012

Individuals with positive family history of liver cancer more likely to develop HCC

A family history of liver cancer is reported to increase risk of developing hepatocellular carcinomas (HCC), independent of hepatitis according to findings published in the May issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. The study also shows 70-fold elevated risk of HCC in those with liver cancer in the family and markers for hepatitis B (HBV) or hepatitis C.

25 Apr 2012

Severe fibrosis increases early atherosclerosis risk in patients with chronic HCV-1 infection

Italian researchers report that severe fibrosis increases the early atherosclerosis risk in patients with genotype 1 chronic hepatitis C virus (HCV) infection. A second study found that fatty liver disease also increases risk of developing atherosclerosis at an earlier period. Both studies appear in the May issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

25 Apr 2012

Vietnam asks for international help to tackle mystery skin disease

Vietnam has asked for international aid to get to the bottom of a mystery skin infection that has already killed 19 people. More than 170 people in the country's central province of Quang Ngai have reported symptoms reports say.

23 Apr 2012

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.

23 Apr 2012

Soy protein may reduce fat accumulation, triglycerides in the livers of obese persons

University of Illinois scientists report that soy protein may significantly reduce fat accumulation and triglycerides in the livers of obese persons. And they've discovered why it happens: soy restores partial function of that organ's key signaling pathway.

23 Apr 2012

Sequana Medical's ALFApump System safe and effective in managing ascites

Sequana Medical announced that initial results from the PIONEER Clinical Study of its ALFApump System were presented today at the 47th annual European Association for Study of the Liver Meeting in Barcelona.

21 Apr 2012

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data from a descriptive sub-analysis of patients with compensated liver cirrhosis show that up to 43 percent of genotype-1a (GT1a) and up to 71 percent of GT1b hepatitis C virus (HCV) patients achieved sustained viral response (SVR12). SVR12 has been highly correlated with SVR24, which is a recognized indicator of viral cure.

20 Apr 2012

New data provides hope for HCV non-responders

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.

20 Apr 2012

New data shows consolidation of interferon-free revolution in HCV treatment

New data presented at the International Liver Congress 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials confirm that combinations of antivirals offer the hope of shorter, more effective treatment with fewer side effects.

20 Apr 2012

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.

20 Apr 2012

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.

20 Apr 2012

NALFD patients with modest alcohol intake are half as likely to develop NASH

People with nonalcoholic fatty liver disease (NALFD) who consume alcohol in modest amounts - no more than one or two servings per day - are half as likely to develop hepatitis as non-drinkers with the same condition, reports a national team of scientists led by researchers at the University of California, San Diego School of Medicine.

20 Apr 2012

HDAC9 gene can lead to obesity-induced body fat dysfunction

Cardiac researchers at the University of Cincinnati (UC) have found that a certain cellular pathway is linked to obesity-related disorders, like diabetes, heart disease and fatty liver disease.

20 Apr 2012

Childhood obesity positively associated with HCC in adulthood

Childhood obesity is a widespread global epidemic and in parallel with non-alcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease among children. New data presented today at the International Liver Congress- 2012 furthers this concern by showing that childhood obesity is positively linked with developing hepatocellular carcinoma (HCC) - the most common form of liver cancer - in adulthood.

19 Apr 2012

EASL publishes new clinical practice guideline on ALD

EASL today announced the publication of a new clinical practice guideline (CPG) in the area of Alcoholic Liver Disease (ALD), bringing the number of CPGs published to date to eight.

19 Apr 2012

Gut microbiota plays a causal role in development of diabetes and NAFLD

Exciting new data presented today at the International Liver Congress 2012 shows the gut microbiota's causal role in the development of diabetes and non-alcoholic fatty liver disease (NAFLD), independent of obesity.

19 Apr 2012

Two studies show true impact of liver disease across Europe

Two studies presented at the International Liver Congress- 2012 show the true impact that liver disease has across Europe. One highlights the financial cost of liver disease to the community and the second highlights the high mortality rates associated with cirrhosis.

19 Apr 2012

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy.

19 Apr 2012

Liver Disease News and Research

Further Reading

IGF-axis proteins may have a role in development of type 2 diabetes

High fructose intake may increase risk of NFALD in obese people

Individuals with positive family history of liver cancer more likely to develop HCC

Severe fibrosis increases early atherosclerosis risk in patients with chronic HCV-1 infection

Vietnam asks for international help to tackle mystery skin disease

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

Soy protein may reduce fat accumulation, triglycerides in the livers of obese persons

Sequana Medical's ALFApump System safe and effective in managing ascites

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data provides hope for HCV non-responders

New data shows consolidation of interferon-free revolution in HCV treatment

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

NALFD patients with modest alcohol intake are half as likely to develop NASH

HDAC9 gene can lead to obesity-induced body fat dysfunction

Childhood obesity positively associated with HCC in adulthood

EASL publishes new clinical practice guideline on ALD

Gut microbiota plays a causal role in development of diabetes and NAFLD

Two studies show true impact of liver disease across Europe

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News